LINC00852 and prostate carcinoma: Overexpression of LINC00852 could increase the expression of JARID2 in prostate cancer cells, and miR-29a-3p mimics reversed the cell promotion under overexpression of LINC00852 through targeting on JARID2 in prostate cancer cells.